Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease
Tóm tắt
Sickle cell disease (SCD) patients are at a four- to 100-fold increased risk for thrombosis compared with the general population, although the mechanisms and risk factors are not clear. We investigated the incidence and predictors for thrombosis in a retrospective, longitudinal cohort of 1193 pediatric and adult SCD patients treated at our institution between January 2008 and December 2017. SCD diagnosis and thrombotic complications were identified using International Classification of Diseases coding and verified through medical chart review. Clinical and laboratory data were extracted from the medical records. With a median follow-up of 6.4 years, 208 (17.4%) SCD patients experienced 352 thrombotic events (64 strokes, 288 venous thromboembolisms [VTE]). Risk factors for stroke included older age and HbSS/Sβ0-genotype and a lower hemoglobin (Hb) F% in the subset of HbSS/Sβ0-genotype patients (P < .05). VTE risk was independently associated with lower estimated glomerular filtration rate, hydroxyurea (HU) use, HbSS/Sβ0 genotype, and higher white blood cell (WBC) counts and Hb (P ≤ .03). Two thrombomodulin gene variants previously associated with thrombosis in the general African American population, THBD rs2567617 (minor allele frequency [MAF] 0.25; odds ratio [OR], 1.5; P = .049) and THBD rs1998081 (MAF, 0.24; OR, 1.5; P = .059), were associated with thrombosis in this cohort. In summary, thrombotic complications are common, and several traditional and SCD-specific risk factors are associated with thrombotic risk. Future studies integrating clinical, laboratory, and genetic risk factors may improve our understanding of thrombosis and guide intervention practices in SCD.
Tài liệu tham khảo
Kato, 2009, Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions, Am J Hematol, 84, 618, 10.1002/ajh.21475
Ataga, 2007, Hypercoagulability in sickle cell disease: new approaches to an old problem, Hematology Am Soc Hematol Educ Program, 2007, 91, 10.1182/asheducation-2007.1.91
Wong, 2005, Overt and incomplete (silent) cerebral infarction in sickle cell anemia: diagnosis and management, Hematol Oncol Clin North Am, 19, 839, 10.1016/j.hoc.2005.07.006
Woods, 2018, Venous thromboembolism in children with sickle cell disease: a retrospective cohort study, J Pediatr, 197, 186, 10.1016/j.jpeds.2018.01.073
Naik, 2014, Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease, J Thromb Haemost, 12, 2010, 10.1111/jth.12744
Brunson, 2017, Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality, Br J Haematol, 178, 319, 10.1111/bjh.14655
Hernandez, 2016, Novel genetic predictors of venous thromboembolism risk in African Americans, Blood, 127, 1923, 10.1182/blood-2015-09-668525
Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006
Zhang, 2014, Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease, Circulation, 129, 1650, 10.1161/CIRCULATIONAHA.113.005296
Akaike, 1998, Selected papers of Hirotugu Akaike
Therneau
TM
. A Package for Survival Analysis in R. R package version 2.38 (2015). Available at: https://CRAN.R-project.org/package=survival. Accessed 1 March 2018.
Therneau, 2020
R Core Team, 2013, R: A Language and Environment for Statistical Computing
Wickham
H.
tidyverse: Easily Install and Load the 'Tidyverse' (Version 1.2.1). 2017. Available at: https://CRAN.R-project.org/package=tidyverse. Accessed 1 October 2017.
Grolemund, 2011, Dates and Times Made Easy with {lubridate}, J Stat Softw, 40, 1, 10.18637/jss.v040.i03
Robinson
D
, HayesA. broom: Convert Statistical Analysis Objects into Tidy Tibbles (Version 0.5.1). 2018. Available at: https://CRAN.R-project.org/package=broom. Accessed 1 October 2017.
Kassambara
A
, KosinskiM. survminer: Drawing Survival Curves using 'ggplot2' (Version 0.4.3). 2018. Available at: https://CRAN.R-project.org/package=survminer. Accessed 1 March 2018.
Hothorn, 2008, Implementing a class of permutation tests: The {coin} package, J Stat Softw, 28, 1, 10.18637/jss.v028.i08
. tidyforest: A tidyverse workflow for running and presenting a logistic regression model in R. (Version 0.1.0). 2019. Available at:https://github.com/riinuots/tidyforest. Accessed 1 March 2019.
Kumar, 2018, Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study, Blood Adv, 2, 285, 10.1182/bloodadvances.2017012336
Strouse, 2011, The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease, Expert Rev Hematol, 4, 597, 10.1586/ehm.11.61
Adams, 1994, Alpha thalassemia and stroke risk in sickle cell anemia, Am J Hematol, 45, 279, 10.1002/ajh.2830450402
Rees, 2009, Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia, Blood, 114, 742, 10.1182/blood-2009-04-216861
Wattanakit, 2009, Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms, Curr Opin Pulm Med, 15, 408, 10.1097/MCP.0b013e32832ee371
Barbui, 2013, Myeloproliferative neoplasms and thrombosis, Blood, 122, 2176, 10.1182/blood-2013-03-460154
Marchioli, 2013, Cardiovascular events and intensity of treatment in polycythemia vera, N Engl J Med, 368, 22, 10.1056/NEJMoa1208500
Barbui, 2018, Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera, Blood Cancer J, 8, 124, 10.1038/s41408-018-0161-9
Stein, 2019, From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms, Blood, 134, 1902, 10.1182/blood.2019001318
De Stefano, 2018, Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases, Blood Cancer J, 8, 112, 10.1038/s41408-018-0151-y
Maugeri, 2006, Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?, J Thromb Haemost, 4, 2593, 10.1111/j.1538-7836.2006.02194.x
Burn, 2018, Direct oral anticoagulants versus warfarin: is new always better than the old [published correction appears in Open Heart. 2018]?, Open Heart, 5, e000712, 10.1136/openhrt-2017-000712
Boffa, 1998, Thrombomodulin: an overview and potential implications in vascular disorders, Lupus, 7, S120, 10.1177/096120339800700227
Ireland, 1997, Thrombomodulin gene mutations associated with myocardial infarction, Circulation, 96, 15, 10.1161/01.CIR.96.1.15
Wu, 2001, Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease, Circulation, 103, 1386, 10.1161/01.CIR.103.10.1386
Doggen, 1998, A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men, Thromb Haemost, 80, 743, 10.1055/s-0037-1615352
Kunz, 2000, Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction, Blood, 95, 569, 10.1182/blood.V95.2.569
Norlund, 1997, A common thrombomodulin amino acid dimorphism is associated with myocardial infarction, Thromb Haemost, 77, 248, 10.1055/s-0038-1655947
Le Flem, 1999, Mutations in promoter region of thrombomodulin and venous thromboembolic disease, Arterioscler Thromb Vasc Biol, 19, 1098, 10.1161/01.ATV.19.4.1098
Ohlin, 1995, The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease, Blood, 85, 330, 10.1182/blood.V85.2.330.330
Ohlin, 1999, Thrombomodulin gene defects in families with thromboembolic disease–a report on four families, Thromb Haemost, 81, 338, 10.1055/s-0037-1614473
Delvaeye, 2009, Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N Engl J Med, 361, 345, 10.1056/NEJMoa0810739
Shatola, 2019, Blood